Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin

P. E. Thorpe, A. J. Cumber, N. Williams, D. C. Edwards, W. C. Ross, A. J. Davies

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

A covalent conjugate of abrin and anti-human lymphocyte globulin (AHLG) was prepared in an endeavour to create a cytotoxic agent with specificity for human lymphoid cells. The AHLG-abrin conjugate was found to be around 10-fold better able to inhibit 3H-leucine uptake by the human lymphoblastoid cell line, Daudi, in tissue culture than was the control conjugate comprising abrin and normal IgG (nIgG). Both materials were less potent than native abrin. Galactose, which is known competitively to antagonize the binding of abrin to cells, strongly inhibited the toxicities of abrin and the nIgG-abrin conjugate whereas that of ALG-abrin was unimpaired. Thus, at least for Daudi cells in tissue culture, abrin can be made selectively toxic, by linkage to AHLG, towards cells bearing antigens to which the antibody moiety of the conjugate can attach.

Original languageEnglish (US)
Pages (from-to)195-200
Number of pages6
JournalClinical and Experimental Immunology
Volume43
Issue number1
StatePublished - 1981

Fingerprint

Abrin
Globulins
Lymphocytes
Immunoglobulin G
Poisons
Cytotoxins
Galactose
Leucine

ASJC Scopus subject areas

  • Immunology

Cite this

Thorpe, P. E., Cumber, A. J., Williams, N., Edwards, D. C., Ross, W. C., & Davies, A. J. (1981). Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. Clinical and Experimental Immunology, 43(1), 195-200.

Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. / Thorpe, P. E.; Cumber, A. J.; Williams, N.; Edwards, D. C.; Ross, W. C.; Davies, A. J.

In: Clinical and Experimental Immunology, Vol. 43, No. 1, 1981, p. 195-200.

Research output: Contribution to journalArticle

Thorpe, PE, Cumber, AJ, Williams, N, Edwards, DC, Ross, WC & Davies, AJ 1981, 'Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin', Clinical and Experimental Immunology, vol. 43, no. 1, pp. 195-200.
Thorpe PE, Cumber AJ, Williams N, Edwards DC, Ross WC, Davies AJ. Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. Clinical and Experimental Immunology. 1981;43(1):195-200.
Thorpe, P. E. ; Cumber, A. J. ; Williams, N. ; Edwards, D. C. ; Ross, W. C. ; Davies, A. J. / Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. In: Clinical and Experimental Immunology. 1981 ; Vol. 43, No. 1. pp. 195-200.
@article{d473082ac68e49f3aec549204282e080,
title = "Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin",
abstract = "A covalent conjugate of abrin and anti-human lymphocyte globulin (AHLG) was prepared in an endeavour to create a cytotoxic agent with specificity for human lymphoid cells. The AHLG-abrin conjugate was found to be around 10-fold better able to inhibit 3H-leucine uptake by the human lymphoblastoid cell line, Daudi, in tissue culture than was the control conjugate comprising abrin and normal IgG (nIgG). Both materials were less potent than native abrin. Galactose, which is known competitively to antagonize the binding of abrin to cells, strongly inhibited the toxicities of abrin and the nIgG-abrin conjugate whereas that of ALG-abrin was unimpaired. Thus, at least for Daudi cells in tissue culture, abrin can be made selectively toxic, by linkage to AHLG, towards cells bearing antigens to which the antibody moiety of the conjugate can attach.",
author = "Thorpe, {P. E.} and Cumber, {A. J.} and N. Williams and Edwards, {D. C.} and Ross, {W. C.} and Davies, {A. J.}",
year = "1981",
language = "English (US)",
volume = "43",
pages = "195--200",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin

AU - Thorpe, P. E.

AU - Cumber, A. J.

AU - Williams, N.

AU - Edwards, D. C.

AU - Ross, W. C.

AU - Davies, A. J.

PY - 1981

Y1 - 1981

N2 - A covalent conjugate of abrin and anti-human lymphocyte globulin (AHLG) was prepared in an endeavour to create a cytotoxic agent with specificity for human lymphoid cells. The AHLG-abrin conjugate was found to be around 10-fold better able to inhibit 3H-leucine uptake by the human lymphoblastoid cell line, Daudi, in tissue culture than was the control conjugate comprising abrin and normal IgG (nIgG). Both materials were less potent than native abrin. Galactose, which is known competitively to antagonize the binding of abrin to cells, strongly inhibited the toxicities of abrin and the nIgG-abrin conjugate whereas that of ALG-abrin was unimpaired. Thus, at least for Daudi cells in tissue culture, abrin can be made selectively toxic, by linkage to AHLG, towards cells bearing antigens to which the antibody moiety of the conjugate can attach.

AB - A covalent conjugate of abrin and anti-human lymphocyte globulin (AHLG) was prepared in an endeavour to create a cytotoxic agent with specificity for human lymphoid cells. The AHLG-abrin conjugate was found to be around 10-fold better able to inhibit 3H-leucine uptake by the human lymphoblastoid cell line, Daudi, in tissue culture than was the control conjugate comprising abrin and normal IgG (nIgG). Both materials were less potent than native abrin. Galactose, which is known competitively to antagonize the binding of abrin to cells, strongly inhibited the toxicities of abrin and the nIgG-abrin conjugate whereas that of ALG-abrin was unimpaired. Thus, at least for Daudi cells in tissue culture, abrin can be made selectively toxic, by linkage to AHLG, towards cells bearing antigens to which the antibody moiety of the conjugate can attach.

UR - http://www.scopus.com/inward/record.url?scp=0019368314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019368314&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 195

EP - 200

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -